| P50 | author | Erik De Clercq | Q13578863 |
| | Gerhard Pürstinger | Q114401419 |
| | Johan Neyts | Q29460378 |
| P2093 | author name string | Koen Andries | |
| | Armando M De Palma | |
| | Bart Rombaut | |
| | Amy K Patick | |
| | Eva Wimmer | |
| P2860 | cites work | Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs | Q40674388 |
| | Synthesis and antiviral activity of C2 analogs of enviroxime: an exploration of the role of critical functionality | Q42547023 |
| | Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime | Q42549518 |
| | Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479. | Q43036168 |
| | Inhibition of Rhinovirus Replication in Organ Culture by a Potential Antiviral Drug | Q44124666 |
| | Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. | Q44401277 |
| | Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. | Q44890455 |
| | Public health. Is polio eradication realistic? | Q46723139 |
| | Anti-enterovirus activity and structure–activity relationship of a series of 2,6-dihalophenyl-substituted 1H,3H-thiazolo[3,4-a]benzimidazoles | Q56786343 |
| | Failure to demonstrate synergy between interferon-alpha and a synthetic antiviral, enviroxime, in rhinovirus infections in volunteers | Q68044760 |
| | The activity of enviroxime against rhinovirus infection in man | Q72476511 |
| | Conclusions and recommendations of the Advisory Committee on Poliomyelitis Eradication, Geneva, 11-12 October 2006, Part II | Q79414489 |
| | Policy. OPV cessation--the final step to a "polio-free" world | Q81411439 |
| | Infectious diseases. Report concludes polio drugs are needed--after disease is eradicated | Q82858519 |
| | Polio vaccine: the first 50 years and beyond | Q83295886 |
| | Pleconaril, a novel antipicornaviral agent | Q28182006 |
| | In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease | Q28343611 |
| | Activity of 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile (MDL-860) against picornaviruses in vitro | Q28367976 |
| | In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease | Q30448335 |
| | In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity | Q30449635 |
| | Intranasal pirodavir (R77,975) treatment of rhinovirus colds | Q30452921 |
| | Treatment of potentially life-threatening enterovirus infections with pleconaril | Q31918011 |
| | Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives | Q33803519 |
| | AG-7088 Pfizer | Q34183108 |
| | 2'-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus. | Q34575779 |
| | Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment | Q35235988 |
| | Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes | Q35309733 |
| | Controlled trial of enviroxime against natural rhinovirus infections in a community | Q35569043 |
| | Polio eradication, cessation of vaccination and re-emergence of disease | Q35777670 |
| | Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications | Q36008885 |
| | Rhinovirus chemotherapy | Q36468395 |
| | Respiratory syncytial virus infections: recent prospects for control | Q36522190 |
| | Treating viral hepatitis C: efficacy, side effects, and complications | Q36564615 |
| | Selective inhibitors of picornavirus replication | Q37125475 |
| | Dependence of echovirus 9 on the enterovirus RNA replication inhibitor 2-(alpha-Hydroxybenzyl)-benzimidazole maps to nonstructural protein 2C | Q39597272 |
| | The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. | Q39870651 |
| | Discrepancy between infectivity and antigenicity stabilization of oral poliovirus vaccine by a capsid-binding compound. | Q40040756 |
| | The polio eradication effort has been a great success--let's finish it and replace it with something even better | Q40284066 |
| P433 | issue | 4 | |
| P921 | main subject | eradication of infectious diseases | Q1347969 |
| P304 | page(s) | 545-551 | |
| P577 | publication date | 2008-04-01 | |
| P1433 | published in | Emerging Infectious Diseases | Q5235761 |
| P1476 | title | Potential use of antiviral agents in polio eradication | |
| P478 | volume | 14 | |